Hepatits C incidence and prevalence in kidney transplant patients

• Autor(a) principal: Zanotelli, Maria Lucia
• Data de Publicação: 2022
• Outros Autores: R. da Silveira, Themis, M. Correa, Maria C., Chersky, Marisa, P.C. Cantisani, Guido
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Clinical and Biomedical Research
• Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/124810
• topic: Kidney transplant; hepatitis C; serological tests; Transplantado renal; hepatite C; avaliação serológica

OBJECTIVE: To detect the prevalence and the seroconversion of the anti-HCV in renal transplants, while evaluating the presence of this antibody at the time of thetransplant, and during a 1-year follow-up, as well as the possibility of transmitting the disease to the recipient of the contaminated organ.PATIENTS AND METHODS: We investigated the prevalence of anti-HCV infection in 48 kidney transplant recipients, and also in their respective donors. Serumspecimens were collected from the organ recipients right before kidney transplant, and 6 and 12 months after transplant; serum specimens were collected from donors at the time of nephroctomy. The 192 samples were stored at -20º C. The anti-HCV tests used were commercial kits based on synthetic HCV peptides (UBI), enzygnost anti-HCV (Boehringer), and Abbot HCV EIA 2nd generation. In patients with a positive anti-hepatitis C UBI test, the presence of HCV-RNA was verified by polymerase chain reaction .RESULTS: Eleven of 40 patients had positive UBI results, and 12 of 48 had positive EIA anti-HCV results before the transplant. Sixteen patients were anti-HCV positive during the 1-year follow-up. Two patients became positive after 6 months, and one after 12 months. One of these patients was also HCV-RNA positive. No transplant recipient patient with positive anti-HCV before transplant seroconverted after 1 year. Fifty percent of the patients who received a kidney were HCV-RNA positive. Three of 40 donors indicated a positive anti-HCV antibody in the UBI test, and 4 of 48 donors indicated a positive anti-HCV antibody in the Boehringer and EIA tests. Two donors were HCV-RNA positive.CONCLUSIONS: The prevalence of anti-HCV before transplant was high, and the serconversion to positive was low during the follow-up; none of the anti-HCV positive patients seroconverted; the HCV-RNA positive patients did not change to negative after transplant, which indicates the persistence of viral replication even after immunosupression; anti-HCV positive donors, even in the presence of HCV-RNA, did not transmit the infection during 1 year after transplant.